SanBio
Basic Information
- Stock Code
- 4592
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- February 2013
- Listing Year
- April 2015
- Official Website
- https://www.sanbio.com/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Free, Sumitomo Pharma, JCR Pharma, AnGes, Nexel Pharma, PeptiDream, Helios, RenaScience, QualiPS, Takara Bio, QPS Institute, Japan Tissue Engineering, CellSeed
Overview
SanBio is a regenerative cell pharmaceutical development company established in 2013, specializing in central nervous system diseases and leading the industry in research and development of innovative stem cell therapeutics.
Current Situation
SanBio recorded an operating loss of approximately 7.8 billion yen in the fiscal year ended January 2023, but is focusing on innovative technologies in the regenerative medicine field. Its flagship product, the regenerative medicine product 'Akugo,' has received conditional approval for traumatic brain injury patients, offering new treatment options in the medical field. Since its founding, the company has consistently handled everything from development to manufacturing and sales of regenerative cell pharmaceuticals, with a particular focus on therapeutics for central nervous system diseases. Despite significant fluctuations such as management changes and varying drug approval statuses, it is strengthening its R&D framework and aiming for future business expansion. Going forward, it plans to deepen collaboration with regulatory authorities, submit additional data to achieve permanent approval, and pursue business diversification along with pipeline expansion. Future growth hinges on robust clinical data and successful market launches, with the challenge of bolstering competitiveness in the biotechnology market.
Trivia
Interesting Facts
- First domestic company to receive conditional approval for stem cell therapeutics
- Achieved Tokyo Stock Exchange Growth Market listing about 10 years after founding
- Headquarters located in St. Luke's Tower, Chuo-ku, Tokyo
- President and Representative Director is Keita Mori, Chairman is Toru Kawanishi
- Teijin Ltd. is one of the major shareholders
- Approximately 90 employees handling highly specialized fields
- Organization focused on highly specialized R&D
- Stem cell formulation 'SB623' is one of the product names
- Stock actively traded on the Growth Market
- One of the promising stocks attracting attention in the regenerative medicine industry
Hidden Connections
- Management team from Mitsubishi Chemical Group supports technology management
- Advancing international expansion in collaboration with U.S. subsidiary SanBio, Inc.
- Utilizing MHLW conditional approval system for market entry
- Competing technologically with rivals like GNI Group and JCR Pharma
- Rare regenerative medicine company listed on Tokyo Stock Exchange Growth Market
- Close collaboration with universities and medical institutions domestically and internationally in R&D
- Continuing growth while overcoming management challenges from drug approval delays
- Stem cell therapy is a globally注目 cutting-edge medical technology field
Future Outlook
Growth Drivers
- Expansion of regenerative medicine demand and regulatory framework improvements
- Increase in central nervous system disease patients due to aging society
- Product diversification through stem cell technology advancements
- Expansion of medical approvals in domestic and international markets
- Promotion of R&D through industry-academia-government collaboration
Strategic Goals
- Expand approved products domestically and internationally
- Enrich multiple clinical pipelines
- Achieve annual sales exceeding 10 billion yen
- Establish advanced cell manufacturing technology
- Strengthen environmentally low-impact and ethical manufacturing systems
Business Segments
Regenerative Medicine Product Development
- Overview
- Develops and manufactures regenerative medicine products for central nervous system diseases and supplies them to medical sites.
- Competitiveness
- Innovative therapeutic development using the latest stem cell technology
- Customers
-
- University hospitals
- Medical institutions
- Pharmaceutical companies
- Research institutions
- Government health agencies
- Products
-
- Regenerative cell pharmaceuticals for traumatic brain injury
- Cell culture technology
- Clinical trial product supply
Cell Therapy Technology Provision
- Overview
- Provides cell processing technology and clinical trial support services in the regenerative medicine field.
- Competitiveness
- High-precision cell culture technology and extensive clinical expertise
- Customers
-
- Biotech companies
- Pharmaceutical companies
- Research institutions
- Products
-
- Cell processing technology
- Clinical data management
- Technical consulting
Competitive Advantage
Strengths
- Advanced stem cell technology
- Pioneer in traumatic brain injury treatments
- International research network
- Highly specialized R&D team
- Integrated manufacturing and sales system
Competitive Advantages
- Rarity of conditional approval from MHLW
- Specialized product portfolio for central nervous system diseases
- Possession of advanced regenerative medicine technology
- Strong scientific backing from clinical trial data
- Strong management team and expert personnel
Threats
- Risk of approval revocation based on trial results
- Burden of high R&D costs
- Market pressure from competitors' technological innovations
- Strict regulatory review policies
- Changes in market treatment options
Innovations
2024: Conditional Approval Obtained for Akugo
- Overview
- Obtained conditional approval for stem cell transplant regenerative medicine product for traumatic brain injury.
- Impact
- Expands treatment options for patients and provides foothold for market entry
2023: Advanced Stem Cell Transplant Technology
- Overview
- Improved manufacturing technology to enhance quality and safety of stem cell formulations.
- Impact
- Strengthens product reliability and stabilizes treatment efficacy
2022: New Regenerative Medicine Pipeline Development
- Overview
- Initiated R&D of regenerative pharmaceuticals for diseases beyond central nervous system disorders.
- Impact
- Establishes foundation for future business diversification
Sustainability
- Maximizing treatment efficacy through strengthened collaboration with medical sites
- Establishment of ethical cell procurement and management systems
- Introduction of environmentally considerate manufacturing processes
- Transparent disclosure of clinical data
- Thorough employee safety and health education